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Abstract
Objectives: Treatment with intravenous (IV) or intra-arterial
(IA) thrombolysis in patients with acute ischemic stroke
demands careful patient selection and specialized institu-
tional capabilities. Physicians at hospitals without these re-
sources may prefer patient transfer for acute treatment.
Helicopter transport for these patients has been described
but without analysis of the effects of its additional cost. The
authors examined the cost–effectiveness of helicopter trans-
port for patients with acute stroke. Methods: Costs per
additional good outcome and per quality-adjusted life-year
(QALY) were calculated using a computer model. Input
variables included flight, thrombolytic agent, and angiog-
raphy costs; annual cost per patient for long-term care of
symptomatic stroke; percentage of transported patients
treated; percentage of patients receiving IV versus IA
therapy; discount rate; absolute probability of good out-
come; annual mortality with and without treatment; and
quality-of-life modifier. Sensitivity analysis was performed.
Results: Helicopter transport of acute stroke patients to
tertiary care centers for thrombolytic therapy costs $35,000
per additional good outcome and $3,700 per QALY for the
reference case. Cost–effectiveness was sensitive to the effec-
tiveness of thrombolysis but minimally sensitive to most
other input values. Cost per QALY ranged from $0 to
$50,000, as the absolute increase in good outcomes (minimal
or no deficit) ranged from 20% to 5%. Cost–effectiveness
was not sensitive to ranges of helicopter flight costs or the
proportion of flown patients undergoing treatment. Con-
clusions: This model indicates helicopter transfer of patients
with suspected acute ischemic stroke for potential throm-
bolysis is cost-effective for a wide range of system variables.
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The importance of emergency medical services (EMS)
in the care of patients with acute ischemic stroke
has increased with the development of time-limited
reperfusion therapies, including intravenous (IV)1
and intra-arterial (IA) thrombolysis.2,3 Studies of out-
of-hospital stroke care have focused on the abilities of
emergency medical technicians to identify the signs
and symptoms of stroke and accelerate transport of
the patient to the emergency department,4–7 but
thrombolytic treatment of stroke requires expertise
and resources not available at all hospitals to which
patients arrive via ground ambulance. Patients taken
to facilities without acute treatment capability may
require emergent transfer to tertiary centers.
Helicopter air medical transport is often the most
rapid and effective means of accomplishing these
interfacility patient transfers and extends the geo-
graphic reach of specialized treatment centers. An im-
portant role for air medical transport of acute stroke
patients was anticipated at the 1997 National Institutes
of Health conference on implementing the results of
the National Institute of Neurological Disorders and
Stroke (NINDS) recombinant tissue plasminogen acti-
vator (rt-PA) study.8 The importance of using EMS to
get patients to specialized stroke care was emphasized
again in a set of consensus-derived guidelines.9
Several institutions currently are using helicopter
air medial services for this purpose. Articles de-
scribing the experiences of flight programs at the
University of Pennsylvania and the University of
Cincinnati have reported that flying acute stroke
patients is feasible, safe, and potentially beneficial.10,11
Other stroke teams and flight programs have pre-
sented their experiences in abstract form with similar
conclusions. The experiences of these programs
suggest acute stroke transports by air medical services
can be performed, but do little to help determine if
they should be performed. Helicopter transport is an
expensive and limited resource, and to our knowl-
edge the question of cost–effectiveness of air medical
transfer of patients with acute stroke has not been
addressed previously.
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In other settings, air medical transport appears
economically viable. Gearhart et al.12 showed heli-
copter transport was cost-effective in trauma patients,
and the variables under which helicopter transport of
patients with acute myocardial infarction for primary
angioplasty can be cost-effective have been identi-
fied.13 The cost–effectiveness of air medical trans-
fer for stroke treatment may be different, however,
because rt-PA and angiography are expensive thera-
pies even before the cost of helicopter transport is
considered. Furthermore, it may be difficult to effec-
tively select patients for transport to ensure subsequent
eligibility for thrombolysis after arrival at a receiving
hospital capable of providing thrombolytic therapy.
The transport of patients not meeting treatment criteria
would generate substantial medical costs without
prospects for patient or societal benefit. Fagan et al.14
previously found IV thrombolytic treatment of stroke
within three hours of onset to be cost-effective, but the
analysis did not include transport costs or potential IA
treatment. The objective of this study was to evaluate
the cost–effectiveness of using helicopter air medical
services to transport patients with acute stroke to
a tertiary center prepared to provide thrombolysis (IV
or IA) within six hours of symptom onset.
METHODS
Study Design. This analysis uses a cost–effectiveness
model developed and reported following consensus
guidelines for medical cost–effectiveness research
derived by a panel convened by the Public Health
Service.15 We also have attempted to use the best
methods consistent with previous stroke-related cost–
effectiveness research as reported by Holloway et al.16
A linear computer model was developed in a spread-
sheet program (Excel; Microsoft Corp., Redmond,
WA). The intervention studied was transport followed
by treatment with IV thrombolysis, IA thrombolysis,
or no thrombolysis. The alternative to the intervention
was nontransport with no thrombolysis. Patient event
pathways in the model are illustrated in Figure 1. The
complete model is described mathematically in the
Appendix. Conceptually the model is defined by three
sets of parameters: reference population, health care
outcomes, and health care costs.
Study Setting and Population. The reference popula-
tion refers to the assumptions made regarding the
characteristics of the patients in the model. The
reference population used in this study represents
the patients included in the NINDS and Prourokinase
in Acute Thrombo-embolic Stroke (PROACT) trials1,3
and are patients with acute ischemic stroke with
a mean age (6 SD) of 65 6 12 years. We estimate that
preflight screening of requested transfers can be
effective enough such that 65% of patients transported
would be eligible for treatment.4,17 The data of Conroy
et al.11 indicate that 38% of patients would be
transported in the 0- to 3-hour window and 62% in
the 3- to 6-hour period.
Study Protocol
Health Care Outcomes. The parameters of the model
included in the health care outcomes portion of the
analysis refer to the choice of how effectiveness is
measured and the assumptions made about how
well the treatment works. Effectiveness is described
by the frequency of good outcome at 3 months and
by quality-adjusted life-years (QALYs). Frequency of
good outcome at 3 months is the most widely used
stroke outcome measure and is defined as minimal or
no disability as determined by a modified Rankin
score of 0 or 1 at 90 days after the onset of symp-
toms. This measure does not allow comparison of
cost–effectiveness for diseases other than stroke. The
most widely used measure for cost–effectiveness is the
QALY. This measure allows comparison with other
medical interventions and health care conditions.
Derdeyn and Powers18 derived a quality-of-life factor
of 0.66 from prior surveys of symptomatic stroke
patients. These patients reported that, if possible, they
would be willing to trade 10 years of life with their
disability for 6.6 years of life without disability from
their stroke.18
The effectiveness of treatment is based on the
results of the NINDS and PROACT trials,1,3 which
are summarized in Table 1. For the reference case in
this model, we selected an absolute improvement of
13% for IV thrombolysis between zero and three
hours and 9% for IA thrombolysis between three and
six hours. The frequency of good outcome without
treatment was assumed to be 20% based on the
NINDS placebo group. We used a combined absolute
mortality improvement of 3% at one year based on the
trends identified in the thrombolytic trials. Subse-
quent mortality was assumed to be unaffected by
treatment and constant at 10% per year.
Health Care Costs. When asking about health care
costs, the first question is ‘‘cost to whom?’’ This is
termed the perspective of the cost–effectiveness analy-
sis. We used a consensus ‘‘broad health care system’’
perspective. This includes acute and long-term direct
care costs but excludes other costs of disability, such
as lost productivity. Costs are those accrued over the
Figure 1. Patient event pathways in the linear cost–effective-
ness model. IV ¼ intravenous; IA ¼ intra-arterial; t-PA ¼ tissue
plasminogen activator.
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remaining life of the patient discounted at 5%
annually. Accrued financial benefits also are dis-
counted.
Flight costs per patient were derived by dividing
the total cost of running the University of Michigan
air medical service, Survival Flight, in fiscal year 1998
by the number of helicopter patient transports com-
pleted. Average costs per patient were used to pre-
vent bias that may occur if only incremental costs
were used in the analysis. Our cost of $3,749 per pa-
tient is typical according to informal data collected by
the Association of Air Medical Services (Landis D.
personal communication, 2000), although slightly
higher than flight costs reported by Gearhart et al.12
for the Pennsylvania State University flight service
Life Lion (Table 2). We used an rt-PA (alteplase)
acquisition cost of $2,500 per patient as reported by
Fagan et al.14 and estimated angiography costs of
$4,000 per patient. The reported average long-term
care costs for patients with acute stroke ranges from
$10,000 to $50,000 per year.14,18,19 We used a conser-
vative estimate of $15,000 per year for average long-
term care costs for the model. Other routine health
care costs are not included in any arm of the model
because they cancel out when the cost for one al-
ternative is subtracted from another.
Data Analysis. We performed a primary sensitivity
analysis by varying our assumptions on effectiveness,
flight costs, percent of patients eligible for treatment
after arrival, and distribution of patients to IV versus
IA routes of drug delivery. We also performed a
secondary sensitivity analysis on other input factors,
including long-term care costs, which were not imm-
ediately related to thrombolytic therapy or patient
transport but had potentially large effects on the
model.
RESULTS
Analysis of this model shows that air medical trans-
port of stroke patients for thrombolysis is cost-
effective. For the reference case, this intervention cost
$35,000 per additional good outcome and $6,100 per
QALY.
Cost–effectiveness is sensitive to assumptions re-
garding treatment effectiveness but is relatively in-
sensitive to a wide range of other assumptions.
Sensitivity to the magnitude of effectiveness is shown
in Figure 2, in which cost per additional good out-
come is shown on the vertical axis and magnitude
of effectiveness is shown on the horizontal axis. The
three components of effectiveness used in the model
(absolute % increase in good outcome from IV
thrombolysis, absolute % increase in good outcome
from IA thrombolysis, and absolute % improvement in
mortality) range linearly together from zero effective-
ness on the left side to substantial effectiveness on the
right. The horizontal and vertical plotted lines indicate
the cost per additional good outcome in the reference
case, where mortality is 3% and effectiveness is 13%
for IV and 9% for IA. The curve resulting from the
model shows costs rising as effectiveness diminishes
and savings rising as effectiveness increases. Figure
2A shows the sensitivity to effectiveness alone in the
reference case. Additional elements of the sensitivity
analysis are added in the rest of Figure 2. The dotted
lines indicate ranges of cost–effectiveness as flight
costs vary from $2,214 to $4,500 in Figure 2B, as
eligibility varies from 50% to 80% in Figure 2C, and as
the distribution of patients arriving between zero and
TABLE 2. Flight Cost Data from Previously Published








Personnel $ 1,197,115 $ 1,727,520
Capital expenses $ 491,081 $ 911,878
Operations $ 296,796 $ 1,644,927
Administration $ 118,332 $ 114,949
Insurance $ 134,942 $ 213,249
Medical supplies $ 15,685 $ 149,001
Total operating expense $ 2,253,951 $ 4,761,524
Helicopter patient transports 1,018 1,270
Average cost/patient flight $ 2,214 $ 3,749
*The higher estimate, shown at the bottom of the right-hand
column, was selected for use in the reference case.
FY ¼ fiscal year.
TABLE 1. Outcome Data Summarized from the NINDS Trial1 of Intravenous Tissue Plasminogen Activator












Good outcome (mRS \2) IV 39 26 50 13 13
IA 26 17 53 9 9
Mortality IV 17 21 19 4 3
IA 25 27 7 2 3
*The far right column shows the values selected for use in the reference case, which is the absolute effectiveness for each route for
frequency of good outcome and an average of the absolute effectiveness of each route for mortality (to simplify the model).
NINDS ¼ National Institute of Neurological Disorders and Stroke; PROACT ¼ Prourokinase in Acute Thrombo-embolic Stroke; mRS ¼
modified Rankin score.
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three hours for IV thrombolysis and patients arriving
between three and six hours for IA thrombolysis varies
in Figure 2D. In each case, there is some deviation in
cost per additional good outcome with changes in
effectiveness but little deviation through the range of
other assumptions. Figure 3 shows the same sensitiv-
ity analysis for the second outcome measure, cost per
QALY. The results vary little in response to changes in
these assumptions.
The model was modestly sensitive to varying the
assumptions regarding long-term care costs from
$10,000 to $20,000 ($15,000 used in the reference case)
with a median deviation in outcome of about 20%
favoring the cost–effectiveness of transport for treat-
ment as long-term care costs increased. The model
was less sensitive to changes in discount rate and
quality factor.
DISCUSSION
The cost–effectiveness of air medical transport of
stroke patients depends on the effectiveness of avail-
able therapy, but our results suggest that for a wide
range of variables, the cost of helicopter transport and
treatment with IV or IA thrombolytics within six
hours of stroke onset is approximately $35,000 per
additional good outcome and $6,100 per QALY. These
values compare favorably with published examples
suggesting that $200,000 per additional good outcome
or life saved or $50,000 per QALY may be considered
a reasonable cost in light of the benefits.16 Our results
indicate helicopter use for the transport of stroke
patients compares favorably with air and ground EMS
transport of other patient populations. Air medical
transport of trauma patients previously has been
estimated to cost $2,500 per QALY,12 and the use of
advanced life support paramedic systems for cardiac
arrest patients is estimated to cost $8,900 per QALY.20
It also compares favorably with other forms of
treatment for stroke prevention. The use of carotid
endarterectomy for symptomatic patients has been
estimated to cost $4,000 to $50,000 per QALY.16 Finally
the cost-effectiveness of the intervention studied is
well below the median cost of $42,000 per life-year
Figure 2. Sensitivity analysis of the model for cost per additional good outcome. A, Sensitivity to changes in effectiveness. The three
components of effectiveness used in the model (absolute % increase in good outcome from intravenous [IV] thrombolysis, absolute
% increase in good outcome from intra-arterial [IA] thrombolysis, and absolute % improvement in mortality) range linearly together.
The horizontal and vertical plotted lines indicate the cost per additional good outcome in the reference case. B–D, The dotted lines
indicate ranges of cost-effectiveness as flight costs vary from $2,214 to $4,500 (B), as eligibility varies from 50% to 80% (C), or as
distributions of patients arriving between 0 and 3 hours for IV thrombolysis and patients arriving between 3 and 6 hours for IA
thrombolysis varies (D). pt ¼ patient; t-PA ¼ tissue plasminogen activator.
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identified in a compilation of cost-effectiveness anal-
yses of 500 life-saving interventions.21
Proposals to develop specialized ‘‘stroke centers’’
(based on the ‘‘trauma center’’ model) to which pa-
tients would be diverted for acute care and re-
habilitation have met with considerable controversy.
The role of EMS systems in diverting patients to
stroke centers is particularly unclear. Early reperfu-
sion of ischemic brain is likely to be important,
however, to obtaining the best outcome of patients
with acute stroke independent of the designation of
the hospital where it occurs. With or without the
development of stroke centers, patients with acute
strokes at hospitals without the professional or facility
resources to provide optimal initial care should be
transported to more appropriate facilities if that
transport can be done effectively and at a reasonable
cost. This model suggests that acute transports can be
both, even using helicopters, a relatively expensive
interhospital transport modality.
LIMITATIONS
This study evaluates the cost–effectiveness of helicop-
ter transport of stroke patients for thrombolytic ther-
apy, but it does not attempt to compare this mode of
transport with treatment and no transport or with other
modes of transportation. Rapidity of transport of stroke
patients is crucial to reperfusion therapies because
efficacy of treatment decreases with time even within
established treatment windows.22 Some further obser-
vations are apparent: (1) Treatment at the initial
hospital without transport, when possible, is inherently
less expensive and more effective than transport for
treatment; (2) transportation by ground is generally less
expensive than by air and should be more cost-effective
if it can be performed with equal or shorter transport
times; and (3) the best available data suggest that
transport for treatment should be performed by the
quickest means available to maximize effectiveness,
but there are not sufficient data yet to allow a compar-
ison of cost–effectiveness as a function of transport
times.
Several other limitations of this study must be noted.
First, we did not consider the effect of treatment on
length of hospital stay, which was shorter for IV t-PA
patients according to the NINDS data. Had we in-
cluded this factor, the cost–effectiveness of thromboly-
sis would have increased. Second, the perspective of
this study is the total health care system, not any
particular payer or provider. At current inpatient
Medicare reimbursements for acute stroke (approxi-
mately $2,000–$3,000), the use of helicopter transport (if
not separately reimbursed) to facilitate thrombolytic
Figure 3. Sensitivity analysis of the model for cost per QALY. See Figure 2 legend for details.
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therapy could create a substantial net loss from the
perspective of a tertiary care hospital no matter how
cost-effective for society as a whole. Third, although the
results seem robust through a wide range of assump-
tions regarding eligibility, there are few data regard-
ing eligibility or the effectiveness of screening in this
intervention strategy. The potential effects and costs
of screening with new modalities, such as diffusion-
perfusion magnetic resonance imaging and xenon-
enhanced or perfusion computed tomography, are
unknown and not included in this analysis. Finally,
we need to know just how many added patients could
benefit from this strategy. Previously reported data on
the potential impact of air medical transport of patients
with acute stroke suggested the use of helicopters may
extend the geographic reach of a tertiary receiving
hospital to 105 km (65 miles) for IV thrombolytic
delivery (0–3 hours) and to 320 km (199 miles) for IA
delivery (0–6 hours).23
CONCLUSIONS
Our analysis finds that air medical transport of acute
ischemic stroke patients for thrombolysis within six
hours of stroke onset is cost-effective from a broad
health system perspective over a wide range of condi-
tions and should be encouraged.
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¼ Total flight costs þ total treatment costs þ total LTCC
QALYTX  QALYNT
Total flight costs ¼ FC  1
E
Total treatment costs ¼ ½PTIV  DC þ ½PTIA  ðDC þ ACÞ
Total LTCC ¼ Discounted LTCCTX  discounted LTCCNT
Discounted LTCCTX ¼ +
LYTX
i¼1
LTCC  ð1  AETXÞ
ð1 þ DÞi





LYX ¼ 1 þ ð1  FYMX=AMXÞ
AETX ¼ ðPTIV  AEIVÞ þ ðPTIA  AEIAÞ
QALYTX ¼ LYTX  ½ðAETX þ GOÞ þ ð1  GO  AETXÞ  Q
QALYNT ¼ LYNT  ½ðGOÞ þ ð1  GOÞ  Q
COST ¼ total system cost
AGO ¼ additional good outcomes
QALY ¼ quality-adjusted life year
FC ¼ flight costs (per transport)
E ¼ eligibility (% of transported patients)
PTX ¼ percent treated by route X
DC ¼ drug cost
AC ¼ angiography cost
FYMX ¼ first-year mortality with treatment X
AMX ¼ annual mortality with treatment X after
first year
LTCC ¼ long-term care costs per year
D ¼ discount rate
LYX ¼ life-years remaining with treatment X
AEX ¼ absolute percent effect with
treatment X
GO ¼ percent with good outcomes
without treatment
Q ¼ quality factor
tPA ¼ thrombolytic group
IV ¼ intravenous route
IA ¼ intra-arterial route
TX ¼ treatment
NT ¼ no treatment
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